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3Forekomst, dødelighet og risikofaktorer for subaraknoidalblødning
Prospektive analyser av HUNT og Tromsøundersøkelsen
Subaraknoidalblødning (SAB) utgjør omtrent 1-7 % av alle hjerneslag. Forekomsten har blitt 
estimert til å ligge mellom 7 og 10 per 100.000 personår. Det virker som forekomsten er 
relativt stabil over tid og mellom land, unntatt i Finland og Japan, hvor forekomsten er høyere.
Noen studier har antydet at forekomsten har gått noe ned de senere tiår, mens sykeligheten og 
dødeligheten etter SAB fortsatt er høy. Siden blødningen er relativt sjelden, har det vært 
vanskelig å påvise risikofaktorer i prospektive studier, men røyking, høyt blodtrykk, høyt 
alkoholinntak og det å være kvinne er kjent å øke risikoen. Det er mer usikkerhet vedrørende 
kroppsmasseindeks (KMI) og serumlipider. Det er også lite kunnskap om hvilke kjennetegn 
ved pasientene som fører til økt risiko for død etter SAB.
Vi registrerte alle som fikk SAB etter deltakelse i befolkningsundersøkelsene HUNT 1 
og 2 (1984-86 og 1995-97) og Tromsø 3 og 4 (1985-87 og 1994-95) ved hjelp av 
diagnoseregistrene på sykehusene som populasjonene sogner til og Dødsårsaksregisteret. Vi 
identifiserte til sammen 214 pasienter. Vi estimerte forekomst og overlevelse, og studerte 
effekten av risikofaktorer ved hjelp av Cox og Poisson regresjonsanalyser. De fire artiklene 
omhandler forekomst og dødelighet av SAB (artikkel I, HUNT 1 og 2 og Tromsø 3 og 4), 
risikofaktorer for SAB (artikkel II, HUNT 1), KMI og serum lipider og risiko for SAB 
(artikkel III, HUNT 2 og Tromsø 4) og kjønnsforskjeller i risikofaktorer for SAB (artikkel IV,
HUNT 2 og Tromsø 4).
Vi fant at forekomsten av SAB fra 1984 til 2007 var 10,3 per 100.000 personår, 13,3 
hos kvinner og 7,1 hos menn. Insidensen kan ha økt litt siden 1984, noe som kan skyldes 
endring i diagnostikk, men den har vært stabil siden 1995. 30 dagers letalitet var 36 % og 
tenderte til å øke med alder, men forble stabil over de 23 årene i oppfølgningen.
Vi fant en lineær og positiv sammenheng mellom systolisk og diastolisk blodtrykk og
risiko for SAB. Røykere hadde høyere risiko for SAB enn dem som aldri hadde røykt, og det 
kan virke som om risikoen assosiert med røyking er høyere hos kvinner enn hos menn. Det 
kan også virke som om overvekt (KMI 25-29.9) er negativt assosiert med risiko for SAB.
Derimot fant vi ingen sammenheng mellom totalkolesterol, HDL-kolesterol eller triglyserider 
og risiko for SAB i totalpopulasjonen, men hos deltakere under 50 år var HDL-kolesterol 
negativt assosiert med risiko.
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1 Introduction
1.1 Summary
Subarachnoid hemorrhage (SAH) is a type of stroke and accounts for about 1-7 % of all 
strokes. The annual incidence of SAH has been estimated to range from 7 to 10 per 100,000 
person years. The incidence seems to be relatively stable over time and in different countries, 
except for Finland and Japan, where incidence seems to be higher. There may have been a 
decrease in the incidence of SAH over recent decades in high-income countries, but compared 
to the decrease in other types of stroke, the decrease in SAH is likely to be modest. In addition, 
morbidity and mortality remains high. Due to the low incidene of SAH, it has been difficult to 
identify risk factors in prospective studies, but smoking, hypertension, excessive alcohol 
consumption and female sex has consistently been shown to increase the risk of SAH. There 
is more uncertainty regarding body mass index (BMI) and serum lipids. There is also little 
knowledge about the pre-ictal characteristics of the patients leading to increased risk of death 
after SAH.
We identified all patients who experienced an aneurysmal SAH (aSAH) after 
participating in the population studies HUNT 1 and 2 (1984-86 and 1995-97) and Tromsø 3 
and 4 (1985-87 and 1994-95) using the patient administrative databases at the hospitals 
serving the study populations, and the Cause of Death Registry. We identified 214 patients in 
total. We estimated the incidence and survival of aSAH, and studied the association of risk 
factors using Cox and Poisson regression analyses. The four papers concern incidence and
mortality from aSAH (paper I, HUNT 1 and 2 and Tromsø 3 and 4), risk factors for aSAH 
(paper II, HUNT 1), BMI and serum lipids and the risk of aSAH (paper III, HUNT 2 and 
Tromsø 4), and sex differences in risk factors for aSAH (paper IV, HUNT 2 and Tromsø 4). 
We found that the incidence of aSAH from 1984 to 2007 was 10.3 per 100,000 person 
years, 13.3 in women and 7.1 in men. The incidence may have increased since 1984, which 
could be due to changes in diagnostics, but the incidence has remained stable since 1995. 
Thirty days case fatality was 36 % and tended to increase with age, but remained stable 
during the 23 years of follow up.
We found a positive linear association between systolic and diastolc blood pressure 
and the risk of aSAH. Smokers had higher risk of aSAH than never smokers, and it may seem 
that the risk associated with smoking is higher among women than men. Overweight (BMI 
25-29.9) may be negatively associated with risk of aSAH. On the other hand, we found no 
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association between total serum cholesterol, HDL cholesterol or triglycerides with the risk of 
aSAH in the total population. However, among participants under 50 years of age, HDL 
cholesterol was negatively associated with risk.
Clarifications
At the beginning of the thesis, I would like to clarify the literature and the terms used in the 
thesis.
In section 1.2, literature published up to June 2011 have been used, to give an 
introduction to the current status of research related to the clinical presentation, diagnostics, 
treatment, complications and follow up of subarachnoid hemorrhage. However, sections 1.3-
1.6 introduce the field of incidence, morbidity and mortality of SAH as well as risk factors for 
SAH, which is the main topic for this thesis. Therefore, in these sections, only papers 
published in or before 2007 have been included, as this was the status of the field of research 
before we started our work in 2008.
In this thesis, “aSAH” has been used when describing only aneurysmal subarachnoid 
hemorrhages (SAH), “SAH” has been used when describing all types of spontaneous SAHs.
“SAH” is also used when describing several studies where some deal with only aSAH and 
some deal with all types of spontaneous SAH.
1.2 Subarachnoid hemorrhage – clinical presentation, diagnostics,
treatment, complications and follow up
Subarachnoid hemorrhage (SAH) is a type of stroke and accounts for about 1-7% of all 
strokes.1 SAH can occur spontaneously or as a result of trauma. The spontaneous, primary 
bleedings are usually caused by the rupture of a saccular aneurysm of an artery on the basis of 
the brain (aSAH; 85%) or a perimecencephalic bleeding (10%).2, 3 The last 5% consists of a 
variety of rare conditions (cerebral arteriovenous malformations, arterial dissection etc).
Traumatic SAHs are usually excluded from studies of SAH, as it is in this thesis.
Clinical presentation
The cardinal symptom of aSAH is sudden severe headache, often described by the patient as 
“the worst headache of my life”. But headache also accounts for about 1 - 2 % of all 
emergency department visits, of which very few (about 3 % or less) are SAHs.4, 5 Even in the 
emergency department, the positive predictive value of almost instantaneous severe headache 
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is only about 39 %.6 Other symptoms of aSAH include symptoms of meningism; nausea, 
vomiting, photophobia and neck stiffness in addition to headache. Loss of consciousness is 
also common, and can be transient at onset (in about 50 % of all cases) or persisting. Epileptic 
seizures (in about 6 %), and focal neurological symptoms such as dysphasia, sensory or motor 
symptoms are other symptoms of SAH.7 Sudden death or death before the patient reaches 
medical attention occurs in about 10 %.8-10 A recent study proposed that any alert patient with 
an acute non-traumatic headache reaching maximum intensity within one hour and with one 
RUPRUHRIWKHVHVHYHQILQGLQJVDJH\HDUVZLWQHVVHGORVVRIFRQVFLRXVQHVVFRPSODLQWRI
neck pain or stiffness, onset with exertion, arrival by ambulance, vomiting, diastolic blood 
SUHVVXUHPP+JRUV\VWROLFEORRGSUHVVXUHPP+JVhould undergo rapid and 
thorough investigation to rule out aSAH.11
Figure 1. Scanning electron microscopy overview of the subarachnoid space in the 
bulbar segment. (Reprinted from British Journal of Ophthalmology, Killer HE et al, vol 87, 
200312 with permission from Br J Ophtalmol)
Pathological aspects
The disease is called subarachnoid hemorrhage because the bleeding is located under (“sub”) 
the middle of the meninges; the arachnoid mater, and thus fills the subarachnoid space with 
blood. The arachnoid mater was named because of its spider web-like appearance. This is 
shown in Figure 1, which is the scanning electron microscopy appearance of the arachnoid 
mater in the subarachnoid space around the optic nerve.12 The intracerebral arteries at the base 
of the brain, where intracranial aneurysms usually occur (as shown in Figure 2), run in the 
subarachnoid space. Therefore, the blood usually enters the subarachnoid space when the 
aneurysm ruptures. However, intracranial aneurysms can also rupture into the brain tissue, 
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mimicking primary intracerebral hemorrhage, or into the ventricular system, and sometimes 
even into the subdural space.13, 14
The process of aneurysm origin, growth and rupture is not well understood. 
Aneurysms usually occur at sites with increased wall shear stress (WSS), as in the distal 
carina of arterial bifurcations.13, 15 The most common sites for aneurysms are shown in Figure 
2.13 Wall pressures and WSS seem to be increased when there are deviations from normal 
anatomy in the circle of Willis.16 In animal models, intracranial aneurysms have been induced 
by ligation of one of the common carotid arteries, leading to increased wall pressures and 
WSS in the contralateral arteries. In addition, hypertension has been induced by renal 
infarction.17, 18 It has been proposed that the development of aneurysms is initiated by 
endothelial damage and disruption of the internal elastic lamina due to increased WSS.17 The 
process may further include local inflammation and destruction of the vessel wall components 
by macrophages, proteolytic enzymes, and cytokines including interleukins, interferon-
gamma and tumor necrosis factor-alpha. This leads to expansion of the defect, and the 
formation of a saccular aneurysm.17, 19 Weaknesses in the components of the arterial walls 
probably increases the risk of intracranial aneurysms, as patients with inherited connective 
tissue disorders are at increased risk.20
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Figure 2. Base of the brain, with most common sites of aneurysms (circles). (Reprinted 
from Lancet, van Gijn J et al, volume 369, 200713 with permission from the Lancet)
Diagnostics
The diagnosis of SAH is usually established by computer tomography (CT), as seen in Figure 
3. CT scan is the first investigation that should be performed when SAH is suspected, and
should be performed as soon as possible after the onset of headache.13 If a SAH is suspected 
and the CT scan is normal, a lumbar puncture should be performed.21, 22 SAH is present if the
supernatant of the cerebrospinal fluid (CSF) is yellow (xanthochromous) after centrifugation,
as analyzed by spectrophotometry. The yellow color is caused by bilirubin, which is present 
due to degradation of hemoglobin. Bilirubin is only synthesized in vivo. Therefore, if the 
blood stained CSF (taken more than 6 or preferably 12 hours after onset of symptoms) turns 
clear after centrifugation, it is caused by a traumatic tap and not by a SAH.2, 14
15
Figure 3. Conventional CT image of a subarachnoid hemorrhage. The subarachnoid 
blood is seen as white in the basal cisterns and the aneurysm is also visible.
To identify the cause of SAH, CT angiography is usually performed (Figure 4). Its sensitivity 
for detecting aneurysms with a diameter of more than 3 mm, has been shown to be 96%, and 
less for smaller aneurysms,23 and may have improved with advances in CT technology.24 In
case of a negative CT angiography and a strong suspicion of SAH, four vessel catheter digital 
subtraction angiography (DSA) should be performed, as DSA is considered the gold standard 
for imaging intracranial aneurysms.25
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Figure 4. Reconstruction of CT angiography showing a large aneurysm in the left 
middle cerebral artery.
Treatment
Angiography is not only used to identify aneurysms as causes of SAH, but also to plan the 
treatment. Treating the aneurysm is important to prevent rebleeding, which is a serious 
complication of aSAH. The traditional method of treatment has been neurosurgical clipping 
of the aneurysm. This was first performed by the American neurosurgeon Walter E. Dandy in 
1937.26 In short, the procedure includes a craniotomy under general anesthesia. The 
neurosurgeon gently retracts the brain and dissects the subarachnoid space to locate the 
aneurysm, and then places a titanium clip around the neck of the aneurysm. The clip stays 
there permanently and excludes the aneurysm from the circulation, thus preventing it from 
rebleeding. Numerous advances in the management and surgical techniques, including better 
microsurgical techniques and instruments, introduction of the operation microscope, advances 
in anesthetics and intensive-care medicine and better diagnostic facilities, have reduced the 
risk associated with this procedure.27 But still, the clinical condition of several patients is 
judged too bad to undergo surgical treatment after aSAH, aneurysms of the posterior 
circulation and closer to the midline can be harder to treat by neurosurgical clipping, and 
neurosurgical clipping has complications.28, 29
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In 1990, a new treatment modality for intracranial aneurysms, endovascular coiling, 
was introduced for clinical use.30 In short, a catheter is led from the femoral artery to the 
parent artery of the aneurysm, guided by DSA. Thereafter, detachable platinum coils are 
introduced into the aneurysm sac. Thrombosis occurs when the coils react with blood, and 
circulation in the aneurysm is stopped, thereby preventing rebleeding. Endovascular coiling of 
intracranial aneurysms has been widely used since 1995, and it was shown to give better 
outcome than neurosurgical clipping in the International Subarachnoid Aneurysm Trial.27
Coiling is therefore now usually preferred if allowed by the anatomy and position of the 
aneurysm and its relation to adjoining arteries.13, 31 However, there is increased risk of 
rebleeding after coiling, and several authors have raised concerns about the ISAT, so the 
debate about the ideal treatment for intracranial aneurysms is still ongoing.32
Complications
In addition to coiling or clipping of the ruptured aneurysm, the aSAH patients require 
specialized intensive medical treatment. The three main neurological complications in 
patients who survive the initial hours after aSAH are rebleeing, delayed ischemic neurologic 
deficit (DIND, also referred to as clinical or symptomatic vasospasm and delayed cerebral 
ischemia), and hydrocephalus.13
Most deaths occur within the first three weeks after aSAH. Apart from the initial 
bleeding, rebleeding is the event that causes most deaths from aSAH; after rebleeding, 75 % 
of patients die or remain dependent on others for activities of daily living.33 For untreated, 
ruptured aneurysms, the risk of rebleeding is 3 to 4 % - and possibly higher - during the first 
24 hours, and 1 to 2 % per day during the first month. The long term risk is 3 % per year after 
3 months.22, 34, 35
To prevent rebleeding, the aneurysm should be occluded, and this is now usually done
early (within 3 days after ictus).7, 13, 22, 36 Early treatment allows for better and more 
aggressive treatment and prevention of symptomatic vasospasm and DIND, but on the other 
hand, early operation may be a risk factor for DIND.37 Blood pressure should be monitored to 
maintain cerebral perfusion pressure and prevent ischemic stroke.22 A short course of 
fibrinolytic agents, such as tranexamic acid, may be helpful immediately after after aSAH to 
prevent ultraearly rebleeding, followed by early treatment of the aneurysm.22, 38, 39
DIND occurs in about 30 % of all patients, most often between days 4 and 10 after 
ictus,37 and is a significant source of morbidity after aSAH.40, 41 Thick clots of subarachnoid 
blood, especially when completely filling any cistern or fissure, are strong predictors for 
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DIND.42, 43 DIND has traditionally been thought to be caused by vasospasm in the proximal 
intracranial vessels, which is seen as constriction on angiography and increased pulsatility on 
transcranial Doppler examination.41, 44 Therefore, studies have often used angiographic 
vasospasm as a surrogate end point for functional outcome. However, more recent literature 
has reported an imperfect association between angiographic vasospasm and DIND.41, 44, 45 It 
has been suggested that other mechanisms of injury, such as microvascular dysfunction and 
complex neuronal - glial interactions may play a role.40 However, the etiology of both 
angiographic vasospasm and DIND is still poorly understood.41 Nitric oxide, endothelin-I, 
lipid peroxidation, and bilirubin oxidative products may play a part, but the results have been 
conflicting and the end points in the studies have differed,41 thus complicating comparison 
between studies.
Although relatively little is known about the pathogenesis of DIND, different 
treatment strategies have been tried to prevent it.22, 40, 41 In some randomized controlled trials, 
endothelin receptor antagonists and lipid peroxidation inhibitors have decreased the incidence
of vasospasm and/or DIND, but not improved outcome.41, 46 Also, clinical trials investigating 
the effect of magnesium have been inconclusive.40 Studies that have evaluated the effect of 
statins to prevent DIND, have shown a decrease in radiographic vasospam. However, there 
are limited and conflicting results regarding their effect on outcome.40, 47-49 At St Olavs 
Hospital, Trondheim University Hospital, statins are used in patients with increased risk of 
DIND. However, the only drug that has been shown to improve outcome after aSAH, is the 
dihydro-pyridine-type calcium channel blocker nimodipin, though its precise mechanism of 
action, except for its cerebral antivasoconstrictive and antiischemic effect, remains unclear.40,
50, 51 Nimodipin is therefore used routinely after aSAH. However, it has not been shown to
have any effect on angiographic vasospam. Interestingly, the similar L-type calcium channel 
blocker nimocardipin was found to reduce the incidence of angiographic vasospasm, but had 
no impact on outcome after three months.52
Hemodynamic therapy, also called triple-H therapy (including hypervolemia, 
hemodilution and hypertension), may also be used prophylactically and as treatment for 
vasospasm and DIND. The rationale for the triple-H therapy is that the autoregulation of
cerebral perfusion following intracranial hemorrhage is impaired.2, 53 Cerebral blood flow 
therefore varies directly with systemic blood pressure, and can be increased by increasing 
perfusion pressure (through hypertension and hypervolemia) or decreasing viscosity (through 
hemodilution), according to Hagen-Poiseuille law.41 However, recent studies have found that 
hypertension alone may improve cerebral perfusion and that there is no additional effect of 
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hypervolemic and hemodilutional therapy, although randomized controlled trials are needed.41,
54 The incidence of DIND did not differ between groups randomly assigned to normovolemic 
or hypervolemic therapy in the two randomized clinical trials that have been performed to my 
knowledge.55, 56 In addition, the risk of deliberately increasing blood pressure and blood 
volume includes rebleeding from an untreated aneurysm, increased cerebral edema or 
hemorrhagic transformation in areas of infarction, in addition to pulmonary edema, 
myocardial infarction and congestive heart failure.55, 57 The use of triple-H therapy as 
prophylaxis is therefore controversial, but it is used as treatment for established vasospasm.22,
41
Acute hydrocephalus is another well-documented complication after aSAH, and is 
reported to occur in about 20-30 % of patients.22 The standard care for this condition is 
external ventricular drainage, which usually leads to rapid improvement.58 However, 
rebleeding and ventriculitis are possible complications, although the reports about increased 
risk of rebleeding from untreated aneurysms are conflicting.22, 58, 59
In addition to the neurological complications, aSAH patients may experience several 
systemic complications, such as severe hypertension, hypoxemia, electrolyte disturbances,
and electrocardiographic (ECG) changes.13 These ECG changes may mimic acute myocardial 
infarction and may thus lead to erroneous examinations and treatment.60 In an 
echocardiographic study performed in SAH patients at St Olavs Hospital, Trondheim 
University Hospital, we found indices of a hyperdynamic and hypervolemic circulation 
shortly after ictus as compared to one week later and compared to healthy controls, but we
found no signs of reduced global left ventricular function.61
1.3 Incidence of aneurysmal subarachnoid hemorrhage
Several studies have evaluated the incidence of SAH in different countries and time periods. 
The annual incidence of aSAH has been found to range from 7 to 10 per 100,000 person years 
in most regions of the world.62-80 However, the incidence seems to be higher in Finland (about 
20 per 100,000 person years)63, 65, 81, 82 and Japan (about 23 per 100,000 person years).63, 83-88
In Central and South America, India and China, the incidence seems to be lower (about 4 per 
100,000 person years).63, 65, 89-93 The incidence of SAH is sparsely investigated in Africa, and 
there are indications that the incidence of SAH is not as low as previously believed, because 
few high-quality studies have been performed.94-97 There may have been a decrease in the 
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incidence of SAH over recent decades in high-income countries, but compared to the decrease 
in other types of stroke the decrease in SAH is likely to be modest.63, 82
However, different study designs and case finding procedures have been employed in 
studies of the incidence and case fatality of SAH, and the different approaches complicate 
comparisons between studies.98, 99 First, there is a mixture of studies with only aneurysmal 
SAHs or with a combination of both aneurysmal and non-aneurysmal SAHs.63-65, 73, 78, 90, 92, 100
This may be because the incidence of aSAH is relatively low, and because until a few decades 
ago, the distribution of CT and angiography was relatively low in high-income countries,
something that is still true in low-income countries. Most cases (80-85%) of SAH are 
aneurysmal, i.e. caused by a ruptured arterial aneurysm.2, 3 aSAH is a serious disease; at least
one-third of the patients die during the first month,101 and prehospital case fatality is also very 
high (about 10 %.).8, 10, 65, 100 In comparison, two-thirds of non-aneurysmal SAHs are so-called 
perimesencephal bleedings, which usually represent a milder disease, with excellent 
prognosis.3, 102 Combining these two types of SAH will therefore lead to a higher incidence 
and a lower case fatality as compared to studying only aSAHs.
Second, many studies of SAH use hospital discharge registers and causes of death 
registers, and estimates of incidence and case fatality are typically made without careful 
validation of the cases.62, 68, 69, 71, 72, 103, 104 In such register studies, one does not know whether 
angiography or autopsy is performed, and thus cases will consist of a combination of 
aneurysmal and non-aneurysmal SAHs. Incidence rates will also tend to be overestimated in 
register studies, since the diagnoses may not be carefully validated. However, the estimated 
positive predictive value of SAH in register studies has ranged from 75 to 93%.69, 105, 106
Taken together, the results of those studies may lead to an overestimate of incidence rates and 
a corresponding underestimate of case fatality, compared to the results of studies that have 
restricted the cases to aneurysmal SAHs. In general, it may seem that studies performed by 
neurosurgeons use strict diagnostic criteria and only include aneurysmal SAHs, while studies 
performed by epidemiologists include all types of spontaneous SAH, but are larger and use 
better epidemiological and statistical methods. 
Third, there have been different routines for autopsy and different intensity of 
diagnostics, especially in very ill and old patients, in different countries over time. As a 
consequence, different proportions among the possibly eligible patients have been indentified 
and included in different studies. At the extremes are China, where the autopsy rate is very 
low due to cultural tradition,65 and Japan, where even patients dead on arrival at hospitals will 
have a CT scan performed, at least in studies.84, 87
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Fourth, the incidence will differ as to whether probable cases of aSAH are included or 
if only cases with aneurysms confirmed by angiography or autopsy are included.107 This may 
be relevant for elderly patients in particular, since less vigorous diagnostics may have been 
performed in these patients. If only patients with confirmed aneurysms are included in the 
study, several patients will be excluded, although they may have had an aSAH. On the other 
hand is it important to avoid false positive cases.
Fifth, incidence is often estimated in specified age groups and the rates are 
standardized to the general population. This may give different incidence estimates compared 
to studies that have included strokes in all age groups. In addition, some studies provide only 
crude incidence rates or rates adjusted to the population of the country they were performed in, 
making it hard to compare incidence rates across countries.
Sixth, many studies of SAH include relatively few patients, and thus, many studies 
have limited statistical power and therefore low precision in the estimates of effect. 
Community-based studies with “hot pursuit” identification of incident strokes, that may be 
necessary for comparison of stroke incidence in different places and over times, as described 
by Malmgren et al98 and Sudlow et al,99 take longer time to conduct and require much work
and resources. Therefore, many studies have been carried out in small areas over short time 
periods, and include few cases of SAH, the smallest group of strokes.70, 76, 79, 80, 89-91, 108-112
Finally, in both register studies and community-based studies, the population at risk 
for developing first-ever SAH comes from census population data in the study area. These can 
be unreliable in developing countries. Since few populations have censuses each year, the 
number of person years in the denominator often has to be estimated from one or two 
censuses and multiplied by the number of years studied.64, 65, 83, 113 Some people may therefore 
contribute to person years in the estimations of incidence even if they already had a SAH, or 
have emigrated or died from other causes during follow up. On the other hand, in population-
based cohort studies performed in countries with population registers, the participants can be 
followed from baseline and censored when they experience a SAH, move out of the 
catchment area of the study, or die. Thus, the cohort approach makes the incidence estimates 
more precise.
1.4 Morbidity and mortality of aneurysmal subarachnoid hemorrhage
aSAH is a serious disease with high morbidity and mortality. Thirty days case fatality has 
ranged from 8 % to 67 % in different studies, but in most studies, thirty days case fatality 
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varies from 30 to 50 %.65, 66, 68-71, 73, 76, 77, 79, 81, 85, 88, 91, 95, 100, 109-111, 113-128 In addition, 10-20 % 
of all patients remain dependent on others for activities of daily life after the SAH,101 and 
even patients with good recovery, who have resumed independent living (about 30 %), 
experience problems after the SAH.2, 129-133 These problems include changes in personality 
(often anxiety, irritability or emotionality), cognitive dysfunction, reduced working capacity, 
higher depression scores than the general population, and generally lower quality of life.130-132,
134, 135 There are indices of improvement of functional outcome and quality of life between 4 
and 18 months after ictus.132 Because of the high morbidity and mortality, and because the 
bleeding often occurs at a relatively young age, the loss of productive life years in the general 
population is comparable to that from cerebral infarction, the most common type of stroke.136
Thirty days case fatality after aSAH may have improved somewhat over the last four
decades, by about 0.5 % per year.101 This may be due to advances in surgical and medical 
treatment of the patients. The introduction of endovascular coiling in the 1990s may also have 
improved prognosis, as patients whose aneurysms or clinical status made them unsuitable for 
neurosurgical clipping of the aneurysm, now can be treated with endovascular coiling. 
Corresponding to the decrease in case fatality, however, the proportion of patients who are 
dependent on others for activities of daily life may have increased.101
The same discussion as in section 1.3 about different study designs and case finding 
procedures that have been employed in incidence studies of SAH, also apply for the estimates 
of case fatality. Thus, inclusion of non-aneurysmal SAHs, use of registers without case 
validation, different intensity of diagnostics and case finding, and small sample size, will 
make estimates less precise and studies less comparable.
Several characteristics of aSAH have been associated with early death or long term 
dependency on others, as was also mentioned in section 1.2.7, 13, 29, 33, 137-140 These 
characteristics mainly include the patients’ neurological condition at admission (evaluated by 
Glasgow Coma Scale score and Hunt and Hess grade or the World Federation of Neurological 
Surgeons scale grade), age, the amount of blood in the initial CT image, and the clinical 
management of the patient. However, few studies have used pre-ictal patient information to 
predict outcome.140-143 One study found that the risk of death from SAH in smokers was 
almost half that of nonsmokers,141 whereas other studies have reported no differences in 
outcome according to smoking status.142, 143 Hypertension was associated with poor outcome 
in one study,140 while another found no association.143 Heavy drinking and low income has 
also been found to impair the outcome after SAH.143, 144 Regarding radiographic vasospasm 
and DIND, one study reported that use of aspirin before the aSAH was associated with 
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reduced risk of DIND with permanent neurological deficit and reduced risk of cerebral 
infarction, as compared to those who had not used aspirin.145 Other studies have found that 
pre-ictal smoking increases the risk of vasospasm and DIND,146-148 but as discussed in section 
1.2, this does not necessarily correlate with outcome. In addition, smoking after ictus, when 
cerebral blood flow is reduced, may increase the risk of vasospasm.149
1.5 Risk factors for aneurysmal subarachnoid hemorrhage
Since aSAH often occurs in relatively young people and both mortality and morbidity are 
high, defining risk factors for development of aneurysms and aSAH is important from a
public health perspective. However, due to the low incidence of aSAH, it has been difficult to 
identify risk factors in prospective studies. Many studies of SAH have been retrospective in 
design, and therefore possibly prone to bias in selection and information.150-160 In addition, 
most of these studies selected patients (for instance hospitalized patients, only one sex or 
excluding those dying shortly after ictus) or studied only a few risk factors. Prospective 
studies have been also performed. However, many prospective studies have included a small 
number of SAH cases, and the case finding and case ascertainment have varied. In addition, 
several studies have included limited age groups and only either men or women.161-169
Nonetheless, smoking, hypertension and female sex have consistently been found to 
be associated with increased risk of SAH.150, 151, 153, 154, 156, 158, 160, 164, 170-180 Excessive alcohol 
consumption (defined in different studies from 150 grams of ethanol per week to 480 grams 
of ethanol per week) has also been found to be associated with increased risk.150, 152, 153, 161, 163,
171, 172, 181 However, studying risk associated with alcohol consumption can be difficult; self 
report of alcohol consumption has been found to be unreliable, leading to misclassification. In 
addition, since studies of risk factors of SAH have generally been relatively small, it has not 
been easy to define a “threshold consumption”, over which alcohol consumption is associated 
with increased risk of SAH, and the cut-off points for light, moderate and heavy alcohol 
consumption have varied between studies. This may be the reason why several studies have 
found no association between alcohol consumption and risk of SAH.154, 172, 173
Other factors have less consistently been associated with risk of SAH. The 
associations of body mass index (BMI) and serum lipids with risk of SAH remain 
uncertain.172 Some studies have reported a negative association of BMI with risk of SAH,156,
170, 171, 182 while others have found no association.173, 174, 183
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The association of total serum cholesterol has also shown inconsistent results: some
studies have reported no association,167, 168, 170, 173, 174, 184 whereas others have reported a 
negative association with the risk of SAH.154-156, 182, 185 One study also found a positive 
association, but this was a relatively small, retrospective case-control study and therefore 
prone to bias.158 Also, most studies with negative associations were retrospective case-control 
studies, and the results may therefore be distorted by bias and reverse causality.154-156, 172, 182
Few studies have assessed HDL cholesterol with the risk of SAH, but two studies have 
reported an inverse association between HDL cholesterol and the risk of SAH.158, 183 Also, 
few studies have assessed the effect of serum triglycerides in relation to SAH, but one 
hospital-based case-control study found a negative association.155
The association of regular physical activity and the risk of SAH is not clear.172, 186, 187
However, moderate to extreme physical exertion have been associated with increased risk of 
SAH in the hours following the activity,187, 188 but the number of cases associated with this 
physical exertion was low in these studies. Other activities that may precipitate a SAH include 
defecation, micturition and sexual activities.188, 189 It is likely that transient elevations in blood 
pressure during these activities may cause rupture of an intracranial aneurysm.187-189
The results from studies that have assessed the influence of meteorological and 
temporal factors on the incidence of SAH have varied, but there are indications that the 
incidence may be somewhat higher in the winter and spring,190 in the morning (as compared 
to the night) and on Sundays (as compared to Mondays).190
People with a family history of aSAH are at increased risk of developing aSAH, 69, 153,
160, 171 and the population attributable proportion of a positive family history has been 
estimated to about 10 %.191 In addition, certain heritable diseases have been associated with 
increased risk of aSAH. Thus, patients with autosomal dominant polycystic kidney disease 
have increased risk of aSAH, but they constitute a very small proportion of all SAH
patients.192 These patients tend to experience the bleeding at a young age, with an equal sex 
distribution (no female preponderance), and a greater tendency for large aneurysms.192 There 
is also evidence that the risk of SAH is increased in patients with other heritable connective 
tissue disorders such as Ehlers-Danlos syndrome type IV, neurofibromatosis type I, and 
Marfan’s syndrome.20
Other risk factors that have been associated with increased risk of SAH include
excessive coffee consumption,174 and cocaine use.156 In addition, it has been suggested that 
non-white ethnicity may be a risk factor for SAH,172, 181, 182, 193, 194 and that low socioeconomic
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status is associated with increased risk of SAH.144, 156, 171, 181, 182, 195 However, the association 
of socioeconomic status  may be explained by differences in risk factor profiles.144, 172
Genetic studies of aSAH have also been performed, but these will not be discussed 
here, since the genetic studies comprise a large and complicated field of study which is not 
directly relevant the work in this thesis.
The association of endogenous and exogenous hormonal factors with the risk of SAH 
have also been studied. These studies will be discussed in the following section.
1.6 Sex differences in risk factors for aneurysmal subarachnoid 
hemorrhage
Unlike other cardiovascular diseases, aSAH affects women more often than men.63, 64, 196
Therefore, some studies have evaluated the association of exogenous hormonal factors, such 
as use of hormone replacement therapy (HRT) and oral contraceptive pills (OC), and
endogenous hormonal factors, such as age at menarche and menopause, number of children 
and age at first birth, with risk of SAH. 
HRT has been found to be negatively associated with the risk of SAH, although the 
associations did not reach statistical significance in all studies.165, 172, 182, 197-199 This may be 
because of lack of power due to few cases using HRT or dilution because of different types of 
HRT and different exposure times of the women. One hypothesis as to why HRT might be 
protective in relation to SAH, is that the fall in estrogen at menopause may lead to a fall in 
collagen in the connective tissue, as it does in skin and bone after menopause.200 This may 
thereby predispose to formation of intracranial aneurysms, which may be prevented in some 
part by the use of HRT.201 The finding that the gender discrepancy in SAH seems to increase 
after menopause,63 may support this hypothesis. However, as relatively few women use HRT 
over a relatively short time period, this does probably not affect the incidence of SAH to a 
large extent.
Concerning OC, it may seem that earlier versions of the pill, containing larger doses of 
estrogen than the modern pills, could have increased the risk of SAH, compared to never 
using OC.157, 162, 202-204 However, the increased risk was not consistent across studies, and 
there seems to be no association of the new formulations of OCs and risk of SAH.172, 182, 199,
204 One study found a higher six months case fatality among ever users of OCs as compared to 
never users.203
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Concerning endogenous hormonal factors, one study found that having the first child 
after the age of 22 years was associated with decreased risk of SAH.182 However, that study 
found no associations of other endogenous hormonal factors, such as age at menarche, parity, 
breast-feeding status, menopausal status, age at menopause, reason for menopause or number 
of fertile years. Another study found that a relatively higher proportion of SAHs had occurred 
shortly before or during menstruation.199
Taken together, studies of hormonal factors and the risk of SAH may indicate that 
estrogen may be protective, at least in postmenopausal women.182 The results may also 
indicate that changes in serum levels of estrogen, rather that the absolute level, may increase 
the risk of SAH.199 Changes in serum levels of estrogen occurs at menopause but are reduced 
by the use of HRT. Serum levels of estrogen also vary throughout the menstrual cycle, and the 
fall before menstruation is probably higher in women using older OCs containing high levels 
of estrogen than in women not using OCs or using newer versions containing lower levels of 
estrogen. However, changes in serum levels of estrogen would not explain why women are at 
higher risk of SAH as compared to men several years after menopause. 
An alternative approach to study the sex difference in the incidence of SAH could 
therefore be to compare the distribution and strength of risk factors for SAH in men and 
women. As discussed above, the major risk factors for SAH are smoking, hypertension and 
excessive alcohol intake. These factors are traditionally more prevalent in males than in 
females, although women have been approaching men in the prevalence of smoking during 
the last decades.205, 206 As SAH is more common in women, there may be sex differences in 
the association of these risk factors, but relatively few studies have explored this question. A
meta-analysis of prospective studies found that the risk for aSAH in female ever smokers was
1.9 times than in men; hypertension was 1.3 times more hazardous in females, and excessive 
alcohol intDNHJSHUZHHNZDVWLPHV more hazardous.172 However, the
metaanalysis mainly compared studies that investigated risk factors for aSAH in either a 
female164-166 or a male161, 167-169, 178 population; only three of the studies included males and 
females from the same population.163, 170, 181 Two of these studies only examined the effect of 
alcohol consumption, and not blood pressure or hypertension.163, 181 In the third study, cases 
were identified using a national hospital discharge registry and were not validated.170 In one 
study not included in the metaanalysis, the association between cigarette smoking and the risk 
of SAH seemed to be stronger in women than in men. However, this paper only included 36 
cases of all types of spontaneous SAH.128 Retrospective case-control studies have reported 
conflicting results regarding the strength of risk factors in men and women. One study found 
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higher risk of aSAH in male compared to female smokers,150 other studies reported higher 
risk of SAH in female compared to male smokers (although it did not reach statistical 
significance in two),151, 207, 208 whereas other studies found no sex differences in the strength 
of smoking as a risk factors for SAH.152, 179 The relationship between hypertension and the 
risk of SAH have been reported as stronger in women than men in one case-control study,
although it did not reach statistical significance.151
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2 Objectives
Main objective
To estimate the incidence, mortality and case fatality from aSAH, and to assess effects of 
selected risk factors in large prospective population-based studies in Norway. The specific 
objectives of the papers are as follows:
Study I
To assess the incidence rates, case fatality and pre-ictal risk factors for aSAH mortality during 
the time period from 1984 until 2007 and for different age groups in two large prospective 
studies of the general population.
Study II
To assess the association of common life style factors (systolic and diastolic blood pressure, 
smoking, alcohol consumption, physical activity and BMI) with the risk of developing aSAH 
in a large prospective study of the general population.
Study III
To assess the association of BMI and blood lipids with the risk of developing aSAH in two 
large prospective studies of the general population.
Study IV
To investigate sex differences in the major established risk factors for aSAH (smoking, 
systolic blood pressure, and alcohol consumption) in two large prospective studies of the 
general population.
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3 Materials and Methods
3.1 The Nord-Trøndelag Health Study (HUNT)
Nord-Trøndelag is one of 19 Norwegian counties and is located in the central part of Norway
(Figure 5). The population is stable at about 131,000 inhabitants (2010),209 with a net 
migration out of the county of 0.3% per year (1996-2000). The population is also
homogenous, with predominantly Caucasian inhabitants. The age- and sex-distribution is 
comparable to Norway as a whole, and the mortality and living conditions are similar to those 
of the 18 other counties in Norway.210, 211 The population is served by two local hospitals, in 
Levanger and Namsos, and one central university hospital, St Olavs Hospital, Trondheim 
University Hospital, in Trondheim. Nord-Trøndelag is therefore a suitable community for 
performing prospective cohort studies.
Figure 5. Norway and Nord-Trøndelag county. Adapted from Holmen et al, Norwegian 
Journal of Epidemiology 2003.211
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The Nord-Trøndelag Health Study (HUNT) is a population-based study that has been 
performed three times. From these studies, we use data from the two first waves of the HUNT 
Study, HUNT 1 (1984-1986), and HUNT 2 (1995-1997). The studies have been thoroughly 
described elsewhere.210, 211
All residents aged 20 years and older in Nord-Trøndelag County in Norway were 
invited to participate in the HUNT Study. Of the eligible population, 77,232 (88.1 %)
participated in HUNT 1, and 65,628 (71.2 %) participated in HUNT 2. Of these, 47,715
participated in both studies. In total, as described in paper I, 169 persons who were not 
officially registered as inhabitants of the county at attendance (n=154) or due to previous
SAH (n=15) were excluded from the study, leaving a total of 94,976 people to be included in 
the study (HUNT 1 or 2, or both). The numbers of participants in the individual papers differs 
somewhat since (i) we did not have information on emigration from Nord-Trøndelag to other 
Norwegian counties in papers II and IV, (ii) the case finding was done in three stages, as 
described further in section 3.4, and (iii) participants who experienced an aSAH before 
attendance in HUNT 2 was excluded from papers III and IV. The specific numbers of 
participants are described in the individual papers.
The clinical measurements, laboratory tests, and self-reported information from the 
HUNT studies that were used in this thesis are described in section 3.5.
The HUNT Study is a collaboration between the Faculty of Medicine, the Norwegian 
University of Science and Technology, the Norwegian Institute of Public Health, and Nord-
Trøndelag County Council. The Norwegian Data Inspectorate, the Norwegian Board of 
Health, and the Regional Committee for Ethics in Medical Research approved this study. In 
HUNT 2, all participants gave their informed, written consent to participate.
3.2 The Tromsø study
Tromsø is the largest city in Northern Norway (Figure 6) and the seventh largest city in 
Norway, with its 67,000 inhabitants (2010).209 Its population is also relatively stable.
The Tromsø Study is a population-based study that has been performed six times.212
In this study, we use data from the third and fourth waves of the Tromsø Study. Between
1986 and 1987 (Tromsø 3), all resident men aged 20 to 61 years and all resident women aged 
20 to 56 years in Tromsø, Norway were invited to participate in the Tromsø 3 study. Between 
1994 and 1995, all residents aged 24 years and older were invited to participate in the Tromsø
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4 study. Of the eligible population, 20,606 participated (75.2 %) in Tromsø 3, and 27,158
participated (77 %) in Tromsø 4. Of these, 15,423 participated in both studies. 
Figure 6. Tromsø. Adapted from Holmen et al, Norwegian Journal of Epidemiology 2003.211
In total, as described in paper I, subjects who did not consent to medical research 
(n=203), subjects who participated without being invited (n=65) and subjects not officially 
registered as inhabitants of the municipality (n=80), were excluded from the study. Also, 
subjects with a known history of SAH (n=30) were excluded, leaving a total of 31,753 people 
included in the study. In papers III and IV, using only Tromsø 4, we excluded 276 
participants due to no consent to medical research (n=201), not officially registered as 
inhabitants of the municipality at the date of attendance (n=44), or previous SAH (n=31),
leaving a total of 26,882 subjects to be followed up. The participants of Tromsø 4 gave 
informed, written consent to participate. The study was approved by The Norwegian Data 
Inspectorate, the Norwegian Board of Health, and the Regional Committee for Ethics in 
Medical Research. 
3.3 The Cause of Death Registry
In Norway, the reporting of deaths by physicians and public health officers to the national 
Cause of Death Registry is mandatory. The registry is owned by the Norwegian Institute of 
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Public Health, but the data are collected and organized by Statistics Norway. In addition to 
using information from the local physicians and public health officers, Statistics Norway 
collects supplementary information from other sources, such as the Cancer Registry of 
Norway, the Medical Birth Registry of Norway, and autopsy reports. The classification is 
based on International Classification of Diseases (ICD) codes. Both the underlying and other 
causes of death are reported. The unique 11-digit identification number of every Norwegian 
citizen enables linkage of data from the Cause of Death Registry with other data, such as data 
from the HUNT and the Tromsø studies. In paper II, the information on causes of death was 
complete through December 31, 2005. In papers I, III and IV information on causes of death 
was complete through December 31, 2007.
3.4 Study variables
3.4.1 Definition and ascertainment of aneurysmal subarachnoid 
hemorrhage
We used several techniques to identify aSAH patients. First, data from both the HUNT and 
the Tromsø studies were linked to the National Causes of Death Register at Statistics Norway,
as described in section 3.3, using codes for subarachnoid hemorrhage according to the 
International Classification of Diseases (ICD) version 8, 9 and 10 (codes 430 (ICD 8 and 9) 
and I60 (ICD 10)). Second, we did searches in the hospitals serving the study populations, as 
described further below. For the HUNT population, the case finding for this study was 
performed in three stages. I will describe the case finding in the order it was chronologically 
performed, although this does not correspond to the sequence of the papers.
3.4.1.1 Case finding for paper II
St Olav’s Hospital, Trondheim University Hospital, is the only hospital with a neurosurgical 
department that serves the HUNT population. All patients who survive the acute phase of the 
SAH are treated at the neurosurgical department, and people who live in the area but 
experience a nonfatal SAH outside the area, are usually transferred to this department after 
acute treatment elsewhere.
We identified all patients submitted to St Olav’s Hospital, Trondheim University 
Hospital who were diagnosed with SAH from January 1, 1984 until December 31, 2005. In 
the search we used three different strategies. First, a computerized search of the St. Olav’s 
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Hospital, Trondheim University Hospital’s patient administrative database was used to 
identify patients diagnosed with SAH according to the International classification of diseases 
(8th and 9th revision code 430, and 10th revision, code I60). Second, we did a manual search 
in operation protocols of the department of neurosurgery for patients who were operated with 
clipping of an aneurysm, or patients who had received an external drain between 1984 and 
1986, during a period when the patient administrative database was not complete. Third, as 
mentioned above, we could identify patients from the catchment area of the HUNT Study 
who died from SAH from 1984 to 2005 based on information from the Cause of Death 
Registry in Norway.
The 1373 patients who were identified through these procedures were individually 
linked to the database of the HUNT Study. Among all the identified patients 225 had 
participated in the HUNT 1 study. Of these, 94 were excluded from further analyses, as they 
were non-aneurysmal SAH, traumatic SAH, SAH caused by arteriovenous malformation, 
other types of cerebral bleeding, or SAH likely caused by antithrombotic or anticoagulation 
therapy. Also, some patients were erroneously coded in the hospital charts, the diagnostics 
were too sparse, or the hospital charts could not be found, and there was therefore probably 
erroneous coding in the hospital charts or the Cause of Death Registry, respectively. In 
addition, five patients had SAH prior to participating in HUNT 1 and were therefore excluded. 
Paper I thus included 132 patients who had a verified diagnosis of aSAH after participation in 
HUNT 1.
3.4.1.2 Additional case finding for paper IV in the HUNT population
In addition to the patients identified for paper II, we extended the search in the patient 
administrative database at St. Olav’s Hospital, Trondheim University Hospital and the Cause 
of Death Registry until December 31, 2007. We identified 18 patients who had aSAH in 2006 
or 2007, and excluded 43 patients with SAH prior to participation in HUNT 2 or Tromsø 4.
In total, paper IV included 69 patients who had a verified diagnosis of aSAH after 
participation in HUNT 2, in addition to those who had participated in Tromsø 4 (n=51), as
described below.
3.4.1.3 Additional case finding for papers I and III in the HUNT population
As mentioned above, St Olav’s Hospital, Trondheim University Hospital is the only hospital 
with a neurosurgical department that serves the HUNT population, and all patients who 
survive the acute phase of the SAH are treated at this neurosurgical department. We first 
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thought that we would be able to identify practically all SAH patients who survive the acute 
phase by searching in the patient administrative database in this hospital, and practically all 
SAH patients who die shortly after ictus by linkage to the Cause of Death Registry. However, 
as it is especially important to identify all patients in a paper of incidence, we decided to 
expand the search before writing paper IV. As paper III was to be submitted after the 
extended search was performed, these patients were also included in paper III. 
We used three techniques to ascertain that we did not miss any SAH patients. First, we 
searched in the patient administrative database in the local hospitals in Nord-Trøndelag; 
Levanger and Namsos Hospitals. We identified three new patients with aSAH after 
participation in the HUNT study, and seven patients who had SAH before participation and 
who therefore were excluded from further analyses. 
Second, we confirmed our search strategy by searching also for patients who had had 
surgical clipping or endovascular coiling of an aneurysm at St Olav’s Hospital, Trondheim 
University Hospital, in case of misencoding. By this search we found one new aSAH patient
who had participated in the HUNT Study. 
Third, two experienced neurosurgeons (T.B.M. and A.V.) and a radiologist reviewed 
the CT images for patients who had received the diagnosis of ICH at a local hospital and who 
died within 6 months in the years 2003 to 2007. This was also done in case of misencoding, as 
some ICHs can be caused by ruptured aneurysms. The 6 months limit was set because aSAH 
patients not treated for their aneurysm are likely to experience recurrent bleeding within 6 
months and thereafter die or be identified as aSAH case. We found no new patients who had 
participated in the HUNT study in this search.
In total, paper I included 157 patients who had a verified diagnosis of aSAH after 
participation in HUNT 1 or 2, in addition to those who had participated in Tromsø 3 or 4 
(n=57), as described below. Paper III included 71 patients who had a verified diagnosis of 
aSAH after participation in HUNT 2, in addition to those who had participated in Tromsø 4 
(n=51).
3.4.1.4 Case finding in the Tromsø population
In Tromsø, a similar procedure was followed at the University Hospital of North Norway, 
Tromsø, which is also the local hospital for the Tromsø population. Adjudication of 
hospitalized and out-of hospital first-ever aSAH was performed by an independent end point 
committee and based on data from hospital and out-of hospital journals, autopsy records, and 
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death certificates. The end point committee also adjudicated other types of stroke, thus, also 
finding misencoded ICHs (n=2). 
In total, paper III and IV included 51 patients who had a verified diagnosis of aSAH 
after participation in Tromsø 4, and paper I included 57 patients who had a verified diagnosis 
of aSAH after participation in Tromsø 3 or Tromsø 4.
3.4.1.5 Definition of aSAH
All patients had a CT scan showing SAH of aSAH found at autopsy. Patients with 
conventional or CT angiographic evidence of an aneurysm or with an aneurysm found during 
operation, and patients identified with aSAH at autopsy were included as cases of aSAH 
(paper I, n=185; paper II, n=111; paper III, n=103; paper IV, n=102). Some cases (paper I, 
n=29; paper II, n=21; papers III, n=19; paper IV, n=18) of SAH were also included, despite 
the fact that angiography or autopsy was not performed, because the medical history was 
highly suggestive of fatal aSAH. The inclusion criteria for these patients were (1) sudden 
headache and/or unconsciousness, (2) massive basal SAH on CT scans, and (3) death within 
four weeks. All criteria had to be fulfilled, and all cases were independently reviewed and 
consented by two classified neurosurgeons (T.B.M and A.V) for the HUNT population and 
the independent end point committee for the Tromsø population. Patients were excluded, 
despite fulfilling all the inclusion criteria, if the CT scan showed an intracerebral hemorrhage 
(ICH), unless a typical localization of the ICH close to a possible aneurysm was found. 
Patients were excluded if they had SAH before participation, if the SAH was non-aneurysmal 
or if they had been coded with the wrong diagnosis. 
Individuals who had died or emigrated from Nord-Trøndelag or Tromsø, were 
identified through the Population Register of Norway. Data on emigration from the Tromsø 
study area to other areas within Norway was available from the Population Register of 
Norway for use in all papers, while emigration from the HUNT study area to other areas 
within Norway was not available until preparation of papers I and III, and is therefore not 
included in papers II and IV. This leads to a somewhat different number of participants and 
follow-up time in the papers. Follow-up time was assigned from the baseline date of 
examination (HUNT 1 (1984-86), HUNT 2 (1995-97), Tromsø 3 (1986-87) or Tromsø 4 
(1994-95) in paper I; HUNT 1 in paper II; and HUNT 2 or Tromsø 4 in papers III and IV)
until the first aSAH or until the end of follow-up on December 31, 2005 (paper II) or 
December 31, 2007 (papers I,III and IV), whichever occurred first. Data were censored for 
date of registered emigration or death from causes other than first-ever aSAH. In paper I, 
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patients who participated in two studies were followed from the first date of attendance, but 
for aSAH patients, data on exposure related to survival were collected from the study attended 
most recently before ictus.
3.4.2 Self-administered questionnaires
In all studies, the participants filled in a questionnaire that was included with the invitation
(questionnaire 1), and attended a clinical examination conducted by trained nurses. A second 
questionnaire (questionnaire 2) was handed out at the clinical examination and should be 
completed and returned by mail in a pre-stamped envelope. The questionnaires can be found 
at http://www.ntnu.edu/hunt/data/que (HUNT) and http://www.tromsoundersokelsen.no
(Tromsø, Norwegian only).
According to their answers in the questionnaires, participants were classified as never 
smokers (reference), former smokers, or current smokers. In paper IV, only cigarette smokers 
were included as smokers, whereas participants smoking cigars and pipes were also included
as smokers in papers I-III.
The questions concerning alcohol consumption differed somewhat in the four studies. 
In paper II (HUNT 1), we classified the participants according to alcohol consumption during 
the last 14 days; as total abstinent, no consumption during the last 14 days, but not totally 
abstinent (reference), 1-WLPHVWLPHVRUWRRPXFK,QSDSHUV,,I and IV (HUNT 2 and 
Tromsø 4), we classified participants as (0) total abstinent, (1) drinking less than once a 
month (reference), (2) 1-4 times per month and (3) > 4 times per month. In paper I, the 
categories from HUNT 2 and Tromsø 4 used in papers III and IV were kept and the categories 
from HUNT 1 and Tromsø 3 were reclassified to fit into these categories. For Tromsø 3, those 
answering “never or a few times per year” were categorized as (1); those answering “1-2
times per month” or “once a week” were categorized as (2); and those answering “2-3 times 
per week” or “practically every day” were categorized as (3). For HUNT 1, those answering 
“not during the last 14 days, but not totally abstinent” were categorized as (1); those 
answering “1-4 times” were FDWHJRUL]HGDVDQGWKRVHDQVZHULQJ³WLPHVRUWRRPXFK´
were categorized as (3). After this reclassification, the distribution of participants in the 
different categories was fairly similar between studies.
For physical activity in paper II, we used a score constructed by Nilsen et al,213
combining the three questions concerning physical activity; the average frequency of 
recreational physical exercise in a week, the average duration, and the intensity of the activity. 
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A summary score was calculated by summarizing the responses according to the following 
equation: 1/5 x frequency + 1/3 x intensity + 1/4 x duration. The participants were then 
divided into four separate categories according to their score as highly active, moderately 
active, having low activity and no activity (reference).
3.4.3 Clinical measurements
Among other measurements, clinical measurements included blood pressure, height, and 
weight.
In paper II (HUNT 1), blood pressure was measured using a calibrated mercury 
manometer with a standard cuff size (12 x 14 cm) after a minimum of 2 minutes’ rest.210 The 
first pulse sound (Phase 1) was recorded as systolic pressure, and the level when the pulse 
disappeared (Phase 5) was recorded as diastolic blood pressure. Both pressures were 
registered with an accuracy of 2 mm Hg, and the measurements were repeated 2 minutes after 
the first recording. In the analyses, we used the average value of the 2 measurements of 
systolic and diastolic blood pressure; and in the few cases with only one measurement; this 
was used instead of the average. In papers III and IV (HUNT 2 and Tromsø 4), blood pressure 
was measured using an automatic device (Dinamap, Critikon, Tampa, FL, USA). Cuff size 
was adjusted after measuring the arm circumference. Three recordings were made at 1-
minuntes intervals after 2 min of seated resting.214 The mean value of the second and third 
measurement was used in the analysis. In paper I, blood pressure measurements from HUNT 
1 and 2 and Tromsø 4 as described above was used in the analyses for participants from these 
studies. For participants in Tromsø 3, blood pressure was measured the same way as in 
HUNT 2 and Tromsø 4, except for 2-minutes intervals instead of 1-minutes.215
In paper II, we grouped the participants into the seven categories of systolic and 
diastolic blood pressure. In papers III and IV, we treated systolic blood pressure as a 
continuous variable and estimated hazard ratios according to a 10 mmHg increase. In addition, 
in papers I, III and IV, we estimated risk associated with hypertension, defined as systolic 
blood pressure 140 mmHg and/or current use of antihypertensive treatment.
Body mass index (BMI) was calculated as weight (in kg) divided by the squared value 
of height (in meters). BMI was divided into groups according to the World Health 
Organization (WHO) classification; <18.5 underweight, 18.5-24.9 normal weight (reference), 
25-29.9 overweight, and obese 30 kg/m2.
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3.4.4 Serum lipids
A non-fasting blood sample was drawn from all participants in the HUNT 2 and Tromsø 4 
studies. Serum samples were analyzed for total cholesterol, high-density lipoprotein-
cholesterol (HDL cholesterol), and triglycerides on a Hitachi 911 Autoanalyzer, by enzymatic 
colorimetric methods with commercial kits (CHOD-PAP, Boehringer-Mannheim, Mannheim, 
Germany) at the Central Laboratory at Levanger Hospital and at the Department of 
Laboratory Medicine, University Hospital of North Norway, for the HUNT 2 and Tromsø 4 
population, respectively. Serum HDL cholesterol was measured after the precipitation of 
lower-density lipoprotein with heparin and manganese chloride. In paper III, low HDL 
cholesterol were defined as HDL cholesterol <1.29 mmol/L and <1.03 mmol/L for women 
and men, respectively,216 DQGHOHYDWHGWULJO\FHULGHVZHUHGHILQHGDVWULJO\FHULGHV
mmol/L.216 In these analyses, we adjusted for number of hours since last meal.
3.5 Ethical Approval
The Norwegian Data Inspectorate, the Norwegian Board of Health, and the Regional 
Committee for Ethics in Medical Research approved this study as well as the HUNT and the 
Tromsø studies. In HUNT 2 and Tromsø 4, all participants gave their informed, written 
consent to participate.
3.6 Statistical analyses
In all papers, we used the Cox proportional hazards model to estimate hazard ratios (HRs)
with 95% confidence intervals (CIs). Departure from the proportional hazards assumption was 
evaluated by Schönfelds residuals and by inspection of the log-log plots. Some study factors
(eg, BMI, alcohol consumption, smoking) was categorized, and the risk of aSAH was 
estimated for each category and compared with a defined reference category. Other study 
factors (serum lipids, and blood pressure in papers II and III) were treated as continuous 
variables.
In paper I, we estimated crude incidence rates by sex, study population (HUNT or 
Tromsø) and age-group (20-29 years, 30-39 years…and 0 years). Poisson regression was 
employed to estimate trends in incidence rates over the following time-intervals; 1984-1989,
1990-1994, 1995-1999, 2000-2004, and 2005-2007, thus allowing the assessment of crude
changes in the incidence rates over time, and adjusted for age (in 10-years categories), sex and 
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study population. We also estimated standardized incidence rates using the European and the 
WHO World Populations as standards. In these analyses, the incidence was assumed to be 
null in the group below 20 years of age, as the study included very few participants below 20 
years of age and the incidence is known to be very low in this age group.83 Students t-test was 
used to assess whether mean age at aSAH occurrence differed between groups and linear 
regression was used to assess whether age at diagnosis changed over time.
The difference between the date of aSAH and the date of death or censoring was 
defined as the survival time. In order to study survival after aSAH, the analysis was restricted 
to the first six months following aSAH. Survival was illustrated using Kaplan-Meier plots 
adjusted for age, and Cox proportional hazards model were used to assess survival by sex, 
smoking and blood pressure adjusted for age at aSAH. Case fatality was estimated after 1, 3,
7, and 30 days, and after 6 months following the date of aSAH. Multiple logistic regression 
analysis was used to assess 30 days case fatality according to time period, with adjustment for 
age and study population.
In paper II, we adjusted for age (in 10-years categories) and sex. In subsequent 
analyses, we also adjusted for other potentially confounding factors (systolic blood pressure, 
smoking, alcohol consumption, BMI, physical activity, marital status, and education). 
However, as there was a substantial amount of missing data on smoking and alcohol 
consumption, these estimates were not presented in the table.
In paper III, we adjusted for age (as a continuous variable), sex, smoking and alcohol 
consumption, as we considered these to be potentially confounding factors in the association 
of BMI and serum lipids and the risk of aSAH. To facilitate direct comparisons of the strength 
of effects related to continuous risk factors in paper III, we estimated HRs per standard 
deviation (SD) increase for the respective factors. We also assessed whether the estimated 
associations differed between men and women using appropriate interaction terms. 
Furthermore, we divided the participants’ follow up time into two strata; one for participants 
younger than 50 years of age, and another for participants 50 years of age or older.
In paper IV, we wanted to investigate potential sex differences in the major established 
risk factors for aSAH. The concept of interaction in clinical and epidemiological research has 
created confusion because it describes two different phenomena.217 On the one hand, 
statistical interaction equals effect-measure modification and refers to the need to include an 
interaction, or product term in a statistical model for the model to fit the data well.217, 218 As 
the most widely used statistical models (logistic regression and Cox regression) are 
multiplicative, statistical interaction usually implies departure from a multiplicative model, 
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meaning that the risk of disease in a person with both risk factors is higher (or lower) than 
would be expected from multiplying the risk of each of them. On the other hand is the 
biological interaction, also called departure from an additive model, meaning that the risk of 
disease in a person with both risk factors is higher (syngergism) or lower (antagonism) than 
would be expected from adding the risk of each of them together.
Therefore, in paper IV, the possible multiplicative (i.e. statistical) interaction between 
sex and the risk factors for aSAH (hypertension, smoking and alcohol consumption) was 
assessed using the log likelihood ratio test. Possible additive (i.e. biological) interaction 
between sex and the risk factors for aSAH was assessed by calculating the relative excess risk 
due to interaction (RERI) with 95 % CIs.219, 220 This measure has been shown to perform well 
in Cox proportional hazards models.221 RERI was calculated as RERI=HR11- HR10- HR01+1 
where HRij is the hazard ratio for i = sex (1 = women, 0 = men) and j = the risk factor in 
question (1 = present, 0 = absent). If there is no additive interaction present, the RERI value 
will be 0. RERI values > 0 indicate that the risk of aSAH in women with the risk factor in 
question is higher than would be expected when adding the risk of being a woman and the 
risk associated with the risk factor in question. Thus, there is increased risk of aSAH 
associated with the risk factor in question among women as compared to men. RERI values <
0 indicate decreased risk of aSAH associated with the risk factor among women as compared 
to men.
In paper IV, we adjusted the sex-specific analyses of smoking for age (in 5-years
categories), alcohol consumption and family history of stroke (information on family history 
of SAH was not available).
All analyses were performed using the statistical software Stata for Windows (Version 
10.0 or 11.0, Stata Corp, College Station, Texas).
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4 Main results
4.1 Paper I
Incidence and mortality of aneurysmal subarachnoid hemorrhage in two Norwegian 
cohorts 1984 - 2007
The crude incidence rate was 10.3 per 100,000 person years, 13.3 for women and 7.1 for men. 
The results indicated an age-dependent increase of 2 % per 10 years higher age (HR 1.02, 
95% CI 1.01-1.03), and suggested an increase over time (HR 1.02, 95 % CI 1.00-1.04 per 5-
year period, after adjustment for age, sex and study population). After 1995, the incidence has 
remained stable (HR 0.99, 95 % CI 0.95-1.03). The incidence was higher in the Tromsø as 
compared to the HUNT population (11.9 vs 9.8 per 100,000 person years), after adjustment 
for age and sex. The crude incidence rate for all types of spontaneous SAH (n=272;
aneurysmal, non-aneurysmal, or SAH where the diagnostics were too sparse to establish 
whether it was aneurysmal) was 13.1 per 100,000 person years, 15.8 for women and 10.1 for 
men.
Case fatality for aSAH at 1, 3, 7 and 30 days, and at 6 months, was 14 % (95 % CI 10-
19), 20 % (95 % CI 14-25), 24 % (95 % CI 19-30), 36 % (95 % CI 29-42) and 40 % (95 % CI 
34-47), respectively. The 30-day case fatality tended to increase by age (OR 1.3, 95 % CI 1.0-
1.6 per 10 years of age), and remained stable during the 23 years of follow-up (OR 1.01, 95 %
CI 0.97-1.06 per year, adjusted for age and study population). 
Six months survival of never smoking patients was lower than among current smokers
(age-adjusted HR 1.8, 95 % CI 1.0-3.2), and lower among patients with systolic hypertension 
than in patients without (age-adjusted HR 1.4, 95 % CI 0.9-2.2). However, since the risk of 
aSAH was higher among current smokers than never smokers, current smokers were at higher
risk of dying from aSAH than never smokers (HR 5.6, 95% CI 3.3-9.5).
4.2 Paper II
Risk factors for aneurysmal subarachnoid hemorrhage in a prospective population 
study. The HUNT study in Norway
Systolic and diastolic blood pressures were positively associated with risk (p for trend=0.001
and <0.001, respectively). Compared to the reference level (< 130 mmHg), the risk related to 
systolic blood pressure between 130-139 mmHg was more than two-fold higher (HR 2.3,
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95 % CI 1.4-3.8, adjusted for age and sex), and for systolic blood pressure t 170 mmHg, risk 
was more than three-fold higher (HR 3.3, 95 % CI 1.7-6.3). For diastolic pressure, the results 
showed similarly strong positive associations. The risk of aSAH was higher in former (HR 2.7,
95 % CI 1.4-5.1) and current (HR 6.1, 95% CI 3.6-10.4) smokers, compared to never smokers.
Compared to being normal weight (BMI 18.5-24.9), there was a lower risk (HR 0.6, 95% CI 
0.4-1.0) associated with being overweight (BMI 25-29.9). For alcohol, only total abstinence 
significantly reduced the risk of aSAH (HR 0.3, 95% CI 0.1-0.7). Physical activity did not 
affect the risk of aSAH.
4.3 Paper III
Risk factors for aneurysmal subarachnoid hemorrhage - BMI and serum lipids: 11-year
follow-up of the HUNT and the Tromsø Study in Norway
People who were overweight (BMI 25-29.9) were at lower risk of aSAH, compared to people 
in the normal weight group (BMI 18.5-24.9): the HR adjusted for age, sex, smoking and 
alcohol consumption associated with overweight was 0.7 (95 % CI 0.4-1.0). There was no 
over all association of total serum cholesterol, HDL cholesterol, triglycerides or alcohol 
consumption with the risk of aSAH. There was also no association of low HDL cholesterol or 
elevated levels of triglycerides with the risk of aSAH.
In age-specific analyses, HDL cholesterol was inversely associated with the risk of 
aSAH (HR 0.6, 95 % CI 0.4 to 0.9 pr SD increase adjusted for age, sex, smoking and alcohol 
consumption) in participants younger than 50 years of age, and in participants 50 years and 
older, there was no clear association of HDL cholesterol (HR 1.2, 95 % CI 1.0 to 1.5 pr SD 
increase adjusted for age, sex, smoking and alcohol consumption). The age-specific analyses 
also suggested that the inverse association of overweight was restricted to people 50 years and 
older, and not present in people younger than 50 years.
4.4 Paper IV
Sex differences in risk factors for aneurysmal subarachnoid hemorrhage: a cohort study
Current smoking was associated with increased risk of aSAH in both women and men (HR 
8.88 (95 % CI 4.65-17.01) and HR 2.81 (95 % CI 1.30-6.08), respectively, adjusted for age, 
alcohol consumption, and family history of stroke). The RERI for sex and current cigarette 
smoking, adjusted for age, alcohol consumption, and family history of stroke, was 3.65 (95% 
43
CI 0.87 to 6.43), indicating higher risk of aSAH associated with current cigarette smoking in 
women than in men (additive interaction). There was no evidence of additive interactions
between sex and hypertension or alcohol consumption and the risk of aSAH. There was also 
no evidence of multiplicative interaction between sex and smoking, hypertension or alcohol 
consumption and the risk of aSAH (all p-values >0.1).
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5 Discussion
In these studies, our main goal has been to estimate the incidence, mortality and case fatality
from aSAH, and to assess effects of selected risk factors in large prospective population-based 
studies in Norway. Briefly, our main results may be summarized as follows:
x The incidence of aSAH is 10.3 per 100 000 person years, 13.3 for women and 7.1 for 
men. The incidence increases with age, and has increased slightly over the last 23 
years. Since 1995, the incidence has remained stable.
x Case fatality for aSAH at 1, 3, 7, and 30 days, and at 6 months, was 14 %, 20 %, 24 %, 
36 % and 40 %, respectively. Case fatality increases with age, but has remained stable 
over the last 23 years.
x Never smokers seem to have worse six months survival after aSAH than current and 
former smokers, but smokers have higher mortality from aSAH than never smokers, 
since the risk of aSAH is higher in smokers than in never smokers.
x Increasing systolic and diastolic blood pressure as well as female sex and current 
smoking increase the risk of aSAH. Current cigarette smoking is more strongly 
associated with increased risk of aSAH in women as compared to men.
x Overweight might reduce the risk of aSAH. There were no over all associations of 
total cholesterol, HDL cholesterol, or triglycerides with the risk of SAH in the general 
population. Before the age of 50 years, HDL cholesterol was negatively associated 
with the risk. 
5.1 Strengths of the study
This study has several strengths. First, it is a prospective cohort study. A general advantage of 
cohort studies is that the temporality criterion for causation, that effect precedes outcome, is 
fulfilled, and reverse causality is avoided. In addition, cohort studies are relatively immune to
recall bias, as further discussed in section 5.4.3. As the incidence of aSAH is low, relatively 
few prospective population-based studies have been performed. 
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Second, the study is population based, and the HUNT and the Tromsø studies consist
of the majority of adults in the populations of Nord-Trøndelag and Tromsø. The population 
base of the study makes the findings easier to generalize, minimizes the risk of selection bias, 
and gives us the opportunity to do sub analyses in different groups. Many studies of SAH are 
not population-based or have studied limited age groups or only either men or women.
Third, we have good criteria for case finding and case ascertainment. The unique 11-
digit identification number of all Norwegian citizens ensures complete follow up of all-cause 
mortality and enables us to link the study participants to discharge registers and autopsy 
registers. We reviewed the charts of all identified patients. All cases without proven aneurysm 
were independently reviewed and consented on by two classified neurosurgeons (HUNT) or a 
neurologist and neuroradiologist (Tromsø) before they were included as possible aSAHs or 
excluded from the study. Specifically, it is important that we have been careful only to 
include aneurysmal SAHs, as aneurysmal and nonaneurysmal SAH are two distinctively 
different diseases, as mentioned in section 1.3.
Fourth, the study population is large, HUNT being one of the largest population-based 
cohort studies worldwide. However, as aSAH is a relatively rare disease, the number of cases 
is anyhow somewhat limited, as discussed in section 5.2. 
Fifth, our study group consisted of both experienced neurosurgeons, a neurologist and 
epidemiologists. Together we had expertise in the main fields and good qualifications for 
performing epidemiologic studies of aSAH. 
Therefore, I believe our population-based prospective cohort study, with good criteria 
for case finding and case ascertainment, can give important insight to the epidemiology of 
aSAH.
5.2 Limitations of the study
However, our study also has limitations. First, the case finding was done retrospectively. In 
the HUNT population, case finding was done from 2008 to 2010, whereas in the Tromsø 
population, case finding was done repeatedly at two to three years intervals. Although we 
searched in overlapping sources, both at the local and regional hospitals and via the Cause of 
Death Registry, inaccurate coding of disease in the hospital registries could have resulted in 
loss of some patients, despite the precautions that were taken against this. In addition, we 
could have lost patients who died shortly after the bleeding without autopsy. However, the 1 
day case fatality of 14 % is similar to figures observed in Japanese studies, where the 
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diagnostics of SAH appear to be very rigorous. Therefore, we find it unlikely that we failed to 
include many eligible patients in our study, maybe except for the first years of observation,
mostly due to changes in diagnostics.
We included 29 patients with only suspected aneurysmal SAH. This could be a 
limitation, as we are not absolutely sure an aneurysm is the cause of the SAH in these patients.
However, patients had to fulfill strict criteria to be included, and we performed sensitivity 
analyses comparing results for aSAH with and without these patients, which showed 
essentially identical results. We therefore consider it more correct to include these patients 
than to exclude them, since they are most likely aSAH patients. It can also be considered a 
strength that we critically reviewed all potential cases and included those who fulfilled the 
criteria instead of excluding all patients who did not have a verified aneurysm. Several of 
these patients died before they were subject to angiography or operation, and a bias towards 
less serious cases of aSAH could be introduced by excluding them. Since we had relatively 
strict criteria for inclusion of these patients, it is more likely that we excluded aneurysmal 
SAHs than that we included false positive cases.
As the incidence of aSAH is relatively low, we do not have a large number of aSAH 
patients in our studies, despite the large cohorts. We combined information from two separate 
populations, the HUNT and the Tromsø population, to increase the statistical power and 
precision in papers I, III and IV. The relatively narrow confidence intervals of most of the 
estimates indicate that precision is relatively good. However, we had limited power to detect 
small differences within sub groups, for instance over time (in paper I), between different age 
groups (in paper III), and between men and women (in paper IV). 
As mentioned above, we combined information from two separate populations, which 
could be a possible limitation. However, both population studies share a number of core 
questions and standardized measurements,214 and the case finding and case ascertainment 
were done using similar procedures. We therefore believe the populations are comparable and 
that combining them was helpful to increase the sample size and power of the study. When 
appropriate, we have mentioned the differences between the populations in the respective 
papers.
In paper III, only non-fasting lipid values were available. Total cholesterol and HDL 
cholesterol levels are not strongly influenced by recent food intake, whereas triglyceride 
levels tend to be increased following a meal. However, both fasting and non-fasting 
triglyceride levels have been positively associated with the risk of cardiovascular disease.222
Nonetheless, we adjusted for time since last meal in the analyses, but the results remained 
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identical to unadjusted estimates. In addition, the use of cholesterol-lowering medication 
could influence the results. However, very few (about 1 %) of the Tromsø population used 
such medication, and there is no information on use in the HUNT population, but the use is 
not likely to differ substantially from that in Tromsø. Therefore, it seems unlikely that 
adjustment for cholesterol lowering medication would have substantially altered the results.
Finally, the estimates from epidemiological studies may be distorted by random error 
that reduces the precision, or by systematic errors that may interfere with the validity of the 
results.223 These elements will therefore be discussed more thoroughly in the following 
sections.
5.3 Precision (lack of random error)
The results of epidemiological studies may always be influenced by chance. Error caused by 
chance is called random error, and often referred to and quantified as the precision of the 
estimated associations. In general, there are two ways of increasing precision in a study; one 
is to increase the study size and the other is to avoid misclassifications in the measurements of 
the study. As mentioned above, the number of aSAH cases in our study was relatively small.
The combination of the two cohorts and the inclusion of patients with suspected aSAH but 
without angiography or autopsy, increased statistical power and thereby the precision of the 
findings. Nonetheless, we had limited power to detect small differences within sub groups. 
However, the main findings of the study were precisely estimated, as indicated by narrow 
confidence intervals. 
Most questions and measurements in the HUNT and Tromsø studies are regarded as
good, as indicated by the strength and precision of the results from several studies. We 
therefore believe they are good tools for studying associations with the risk of aSAH, maybe 
with alcohol consumption as a possible exception. This will be discussed in section 5.4.3.
5.4 Validity (lack of systematic error)
As mentioned above, random error is caused by chance. The other main type of error in an 
epidemiologic study is systematic error, often referred to as bias. The opposite of bias is 
validity, and validity and precision are both components of accuracy.223 Validity can be 
divided in internal and external validity. Internal validity is how the inferences drawn from 
the study apply to the members of the population of the study. External validity is how the 
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inferences apply to people outside of that population. External validity is also called 
generalizability and will be discussed further in section 5.4.4. In studies of causation, internal 
validity is considered a prerequisite for external validity.223 Most violations of internal 
validity can be classified in three groups; confounding, selection bias and information bias.
5.4.1 The role of confounding
Confounding can be seen as mixing of effects; the effect of the exposure on the outcome is 
distorted by the effect of another exposure that is associated with, and is a common cause of 
both the exposure of interest and the outcome. Confounding can lead to both an 
overestimation, underestimation and a change in the direction of the estimated effect of 
interest.223
Age and sex are the most obvious confounders in the present studies. This is because 
the risk of aSAH increases with age, and the distribution of different exposures (e.g. smoking 
and blood pressure) varies with age. We therefore adjusted for age in all papers.
Correspondingly, aSAH is more frequent in women, and the distribution of exposures will 
tend to differ by sex. In paper IV, we handled this by conducting sex-specific analyses, 
whereas in the other papers, we adjusted for sex. 
In paper III, where the aim was to assess the associations of BMI and serum lipids 
with the risk of aSAH, we also adjusted for smoking and alcohol consumption. From the 
directed acyclic graph (DAG)224, 225 in Figure 7, we can see that these factors may be 
confounding the association of BMI and risk of aSAH. This is because they are both risk 
factors for aSAH,172 and simultaneously, both smoking and high alcohol consumption are 
associated with low BMI.226 Therefore, if we had failed to take smoking and alcohol 
consumption into account (i.e. controlled for them), we could erroneously have found that low 
BMI was associated with increased risk of aSAH, when in fact there was no association at all, 
since smoking and alcohol consumption are both associated with both BMI and with the risk 
of SAH. A similar reasoning may apply for serum lipids.
49
Figure 7. Directed acyclic graph of the association between BMI and aSAH
In paper IV, we also adjusted for family history of stroke, since family history is a 
potential confounder for the association of smoking and the risk of aSAH. For instance, 
people may be less likely to smoke if a relative had a stroke at a young age and the risk of 
aSAH is higher if a first-degree relative has experienced the disease.69, 160 Since we did not 
have specific information on family history of SAH, we had to use total strokes instead. This 
may have led to residual confounding.
In paper II, we chose to show only the unadjusted estimates in the tables. This was 
done because the amount of missing data on smoking and alcohol consumption in HUNT 1 
would lead to a smaller sample size and less precise adjusted estimates. We did, however, 
include all potential confounders (age, sex, systolic blood pressure, smoking, alcohol, BMI, 
physical activity, marital status and education) in a multivariable model, and these 
adjustments did not substantially influence the results.
In all papers, the estimates remained nearly identical after adjustment for potentially 
confounding factors, implying that little confounding was present. Nonetheless, we cannot 
exclude residual confounding by other, unmeasured factors or by the questionnaire’s inability 
to reflect the true exposure (for instance for alcohol consumption). In any case, the decision 
on whether a factor should be regarded as a potential confounder, should be made based on a
priori empirical substance knowledge, and not after scrutiny of the results.225
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5.4.2 The role of selection bias
Selection bias arises when the relation between exposure and outcome differs between the 
participants and those who are theoretically eligible to participate.223 Self-referral to studies is
usually considered a source of selection bias that may be a threat to validity, because those 
who chose to participate may differ from those who did not participate.223, 227 In both the 
HUNT and the Tromsø studies, all of the general population was invited, and the studies have 
a relatively high attendance rate. In addition, non-participation studies have been performed.
Non-attendance was mostly caused by outside obligations, such as work, and the non-
attendees did not systematically differ from those who attended in any respect that is likely to 
influence their risk of aSAH. However, there may be one exception, since elderly non-
participants tended to have higher morbidity and mortality than elderly participants.211
5.4.3 The role of information bias
Information bias arises due to measurement errors that may distort the association of exposure 
and effect. For discrete variables (e.g. smoking, disease) measurement errors are usually 
called misclassification, and often referred to as either differential or nondifferential, 
according to whether the misclassification is dependent on the actual values of other variables 
(differential misclassification) or not (nondifferential misclassification).
Several of the measurements in the present studies were prone to misclassification. For 
example, random errors will occur in the measurement of serum lipids and blood pressure. 
There may also be information bias in the reporting of smoking and alcohol consumption. 
Excessive alcohol consumption has consistently been shown to be a risk factor for SAH,172
but in this study, the only evident association was a negative association related to being 
abstinent from alcohol (Paper II). However, if only half of the participants acknowledge their 
excessive alcohol consumption, the risk difference and risk ratios between the exposure 
groups will be biased towards the null value due to nondifferential misclassification. In 
addition, the category of people who drink alcohol five or more times per month may consist 
of both people who drink one glass of wine every Saturday and some Fridays and people with 
excessive alcohol consumption. When combining these into one category, we may introduce a 
nondifferential misclassification bias, masking the association between excessive alcohol 
consumption and the risk of aSAH. 
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An inherent assumption in this type of studies is that exposures remain stable over the 
follow-up period. However, this may not be the case for several exposures. For instance, 
participants could have started treatment for hypertension or hypercholesterolemia after 
detection of elevated blood pressure or serum cholesterol in the population study. BMI, 
alcohol consumption and smoking habits are also factors that are prone to change over time. 
The likelihood that exposures change will increase with time, and in our study, some 
participants had the aSAH several years after baseline measurements. Therefore, we cannot 
exclude the possibility that treatment or behavior changes subsequent to the baseline findings 
could have influenced later risk of aSAH. However, little is known about the importance of 
temporal changes in risk factors, and how such changes may interact in the development and 
rupture of intracranial aneurysms. Therefore, previous exposures, detected at baseline in the 
population studies, may be just as important as exposures shortly before the bleeding. The 
strong associations we found for systolic blood pressure and for smoking suggest that baseline 
measurements can give important information that is highly relevant in relation to the risk of 
aSAH. In addition, in the Framingham study, with biannual examinations of all participants, 
both the baseline measurements of systolic and diastolic blood pressures, the measurements 
from the closest examination prior to SAH, and the mean systolic and diastolic blood 
pressures based on all examinations were associated with increased risk of SAH, and 
analogous findings were done in relation to temporal information on smoking.128
The misclassifications mentioned above are likely to be nondifferential, meaning the 
misclassifications do not depend on future aSAH occurrence. For instance, the measurement 
of blood pressure and the reporting of alcohol consumption are not likely to be related to the 
development of aSAH. Whereas most other types of biases are unpredictable in the way they
may distort the estimates of effect, nondifferential misclassification will in most cases
introduce a bias towards the null value since it increases the similarity of the exposure 
groups.223 Several of the estimates of this thesis are therefore likely to be underestimates of 
the true effects.
Detection bias and recall bias are examples of differential misclassification. Recall 
bias is usually a minor problem in a cohort study, since people are asked about their habits 
and examined long before they potentially experience the study outcome, which in our cases 
was aSAH.
There may, however, have been a source of detection bias in our study. Younger 
people who experience symptoms of aSAH may be more likely to be diagnosed than severely 
ill elderly people, and young people who suddenly die are more likely to undergo autopsy
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than elderly people, although this may have changed during the last decades, leading to more 
elderly patients being detected in the last part of the study, as discussed further in 5.5.1. This
misclassification would lead to an underdiagnosis of aSAH in the elderly and a biased higher
risk for younger compared to elderly people. However, we found a strong incidence increase 
related to age.
The Cause of Death Registry ensured that we had complete follow-up information for 
all-cause mortality in our study. Data on emigration from Statistics Norway enabled us to 
censor participants when they moved away from Nord-Trøndelag (in papers I and III) and 
Tromsø (in papers I, III and IV). Loss of follow up, which is usually a major problem in 
prospective cohort studies of the general population, is therefore unlikely to play an important 
role in these studies. However, in papers II and IV, we only had information about people 
who emigrated from Nord-Trøndelag out of Norway. Census data show that about 2500 
persons from Nord-Trøndelag move to other Norwegian counties each year,209 and most of 
these are young people, maybe students, who may move back after a few years. Nonetheless, 
this may have led to an overestimation of person-time in these two studies. However, as we 
mainly study risk factors for aSAH in these papers, this has probably not influenced our 
results to a large degree. In the incidence study (paper I), we had information on all migration 
from both Nord-Trøndelag and Tromsø. 
We used strict criteria to include the aSAH cases, and we therefore believe that the 
specificity of the aSAH cases is close to 100 %, implying that there are no false positive cases. 
The sensitivity, however, may be moderate because we most likely did not detect all patients 
and because we had to exclude patients with potential aSAH if the diagnostics performed 
were too sparse. For most risk factors, this misclassification is likely to be nondifferential. For 
age, however, the misclassification could be differential, as discussed above. In cases with 
perfect specificity and imperfect sensitivity, the hazard ratio will be biased towards the 
null,223 but when the risk of disease is low, as with aSAH, this bias will be small. We 
therefore believe that misclassification of outcome had little impact on the estimated effects of 
risk factors. However, our incidence estimates will probably be somewhat underestimated, 
especially in the oldest age groups.
5.4.4 External validity (generalizability)
It is an important objective of epidemiological studies to obtain estimates of effect that are 
valid for relevant target populations.228 This study is based on population studies with high 
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participation rates including adults of both sexes. The external validity of our results would be 
limited if the associations of interest differed between those who were included in the studies 
and those who were not, or between the adult population of Nord-Trøndelag and Tromsø and 
other adult populations. There is, to our knowledge, no substantial evidence to indicate that 
such differences exist. However, the study consists of mainly Caucasian participants and may 
therefore be less generalizable to other ethnic groups.
5.5 Appraisal of the principal findings
5.5.1 Incidence of aSAH
We estimated the incidence of aSAH to 10.3 per 100,000 person years. Although comparisons 
between studies can be difficult due to different study designs and case finding procedures,98,
99our estimate corresponds well to the findings of other studies from high-income countries.63,
64, 68-71, 103, 104, 229 However, as discussed in section 1.3, the estimates in other studies may both 
be over- and underestimated. We reviewed all patient charts manually and validated all aSAH 
cases. There may have been changes in diagnostics over the last decades, and especially older 
patients may have more diagnostic tests performed during the recent years even if they are 
critically ill. Due to our strict criteria for the aSAH diagnosis, we excluded patients with 
insufficient diagnostic information. Of these excluded patients, more were older than 70 years 
of age and died within two weeks during the two first time periods (1984-94) as compared to 
after 1995. This may have contributed to our finding of no decrease in incidence or case 
fatality during the last 23 years, whereas a moderate decline has been suggested in some other 
studies.9, 63, 82, 101, 116
We found that the incidence was somewhat higher in the northernmost population 
(Tromsø) compared to the HUNT population in the middle of Norway. A north-south gradient 
pattern in the incidence of SAH in Norway and Sweden has been previously suggested,103, 104
but the underlying reason is unclear. The prevalence of current smoking, which is the 
strongest risk factor for aSAH in this population, was higher in the Tromsø population. 
Another possibility could be the higher proportion of inhabitants with Finnish and Sami origin 
in the north. In the Tromsø 3 study population, 6 % were of Finnish and 3 % of Sami origin. It 
is well known that Finns have higher risk of SAH.63 In addition, inhabitants of Sami and
Finnish origin in northern Norway have less favourable cardiovascular risk factor profiles, 
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and inhabitant of Finnish origin are at higher risk of ischemic heart disease as compared to 
inhabitants of majority Norwegian origin.230
5.5.2 Mortality of aSAH
We found a 30 days case fatality of 36 %. Although different study designs and end points
complicate the comparison between studies, our estimate corresponds well to the findings of 
several other studies.1, 9, 64, 65, 69-71, 73, 85, 91, 103, 116, 117, 120, 124, 229, 231, 232 We did, however, not find 
a decrease in the 30-days case fatality, as has been suggested in other studies,9, 101, 103, 116-118
while others have found no decrease.75, 85, 233 As discussed above, this may be due to 
differences in diagnostics, especially since case fatality increases with age.103, 141 In addition, 
our number of aSAH cases may be too low to detect small changes in 30-days case fatality.
Our findings that never smokers may have poorer 6-months survival than current 
smokers, and the similar tendency of poorer 6-months survival in patients without 
hypertension as compared to hypertensive patients were surprising. However, in one previous 
retrospective study without strict criteria for case ascertainment where smoking status was 
determined by medical records, a poorer survival was found in never smokers.141 Other 
studies have found no association between smoking and survival.142, 143 One possible 
explanation for this association, if one should assume it is causal, is that smokers may 
experience less severe aSAHs and less early rebleeding because of elevated serum levels of 
fibrinogen226, 234 and other thrombogenic factors.235 Another possibility is that the increased 
risk of vasospasm found in smokers146, 147 may reduce the severity of the initial 
hemorrhage.141 The better survival may also be attributed to a younger age at hemorrhage,141,
146 but the finding persisted after controlling for age, so age is likely not an explanation for the 
survival differences. Hypertension is used as treatment for vasospasm, 22 which may in part 
explain why hypertensive patients may have better survival. Finally, smoking and 
hypertension could possibly lead to a milder type of aSAH than aSAHs associated with other 
possibly unknown risk factors.
5.5.3 Risk factors for aSAH
We found strong, positive associations between smoking and hypertension and the risk of 
aSAH. The consistency of these findings across different study types and populations,151, 153,
154, 170-175, 236 the dose-response relationships,150, 151, 156, 173, 208 as well as the associations of 
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smoking and hypertension with other cardiovascular diseases,205, 237 suggests that these 
associations may be causal. The mechanisms of how smoking increases the risk of aneurysm 
formation and rupture are not well understood. Smoking may elevate wall shear stress through 
nicotine-induced sympathetic activation238 and increased levels of hematocrit and plasma 
fibrinogen.226, 234, 239 Smoking may also increase inflammation within arterial walls by direct 
effect of tobacco combustion products or through increased blood concentration of white 
blood cells and increased monocyte-endothelial cell adhesion.240 Other proposed mechanisms 
for the increased risk of SAH associated with smoking include increased blood pressure, 
endothelial dysfunction, enhanced atherosclerosis, and increased degradation of elastin in the 
arterial walls due to UHGXFHGDFWLYLW\RIWKHSURWHDVHLQKLELWRUĮ-antitrypsin.179, 208, 241
The mechanisms of how hypertension increases the risk of aneurysm formation and 
rupture are not well understood. However, studies have suggested that hypertension may 
cause intimal lesions,15 and accelerate the process of aneurysm formation due to tensile stress 
in the presence of altered hemodynamics.18, 19 Transient elevations of blood pressure have 
also been proposed to increase the risk of rupture in an intracranial aneurysm.187-189
We found that overweight may be associated with reduced risk of aSAH. This finding 
is in accordance with some previous studies,156, 170, 171, 182 where others have found no 
association.173, 174, 183 If this association is true, the mechanisms are uncertain. It has been 
suggested that low BMI could be a marker of preclinical disease or “poor health”, and that 
higher morbidity and mortality in people with low BMI may be due to confounding or reverse 
causation.242-244 It is also possible that a negative association of overweight with the risk of 
aSAH could be confounded by smoking or alcohol consumption.170, 171 However, the 
association was only slightly attenuated after adjustment for smoking and alcohol 
consumption. It is unlikely that the negative association of BMI is mediated by serum lipids, 
since we found no clear association of any serum lipid and the risk of aSAH, except a 
negative association of HDL cholesterol in participants younger than 50 years of age. 
Few studies have assessed the association of HDL cholesterol and the risk of SAH, but 
one study has reported a negative association.183 Studies of ischemic heart disease and 
ischemic stroke have found a protective effect of HDL that is stronger in middle age than in 
old age.196, 245 Similar age-dependent effects may therefore be plausible in relation to aSAH.
We found no associations between total serum cholesterol or triglycerides and the risk 
of aSAH. Some studies have found no association of total serum cholesterol,167, 168, 170, 173, 174,
184 while others have found a negative association.154-156, 182, 185 However, in these
retrospective studies, the blood samples were drawn after the bleeding had occurred, and the 
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results may therefore be distorted by reverse causality. Few studies have assessed the effect of 
triglycerides in relation to SAH, but one retrospective study found a negative association.155
5.5.4 Sex differences in risk factors for aSAH
Our results suggest that current cigarette smoking is more strongly associated with increased 
risk of aSAH in women than in men. This was also suggested in a meta analysis of 
prospective studies.172 However, as mentioned in section 1.6, the studies in that meta-analysis
had limitations, as the studies either included only one sex,161, 164-169, 178 only studied the 
association of alcohol consumption,163, 181 or had un-validated cases from a national hospital 
discharge register.170
The possible mechanisms for the increased risk of intracranial aneurysms and aSAH in 
women have been sparsely investigated. The proposed mechanisms include hormonal 
factors,63, 159, 182, 199 arterial wall weaknesses due to decreased estrogen after menopause,201
and local sex differences in the hemodynamic forces acting upon the intracranial arteries.246
Our results, suggesting that sex differences in the vulnerability to cigarette smoking
contribute to the sex difference in aSAH incidence is supported by the findings in the WHO 
MONICA study. In this study, an increased incidence of SAH in women as compared to men 
was evident only in populations where the prevalence of current smoking was approximately 
evenly distributed in the two sexes. No sex difference or a male preponderance was found in 
populations where few women smoked.65, 206
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6 Conclusions
1. We found evidence for a moderate incidence increase in aSAH during 23 years of 
follow up, but the increase may be explained by changes in diagnostic procedures. 
Thirty day case fatality has remained fairly stable.
2. We found strong positive associations between blood pressure (systolic and diastolic) 
and current smoking with the risk of aSAH, whereas being overweight may be
associated with reduced risk.
3. We found no over all associations of total cholesterol, HDL cholesterol, or 
triglycerides with risk, but before the age of 50 years, HDL cholesterol was negatively 
associated with the risk of aSAH in this large, prospective population-based study.
4. We found that current cigarette-smoking women have higher risk of aSAH as 
compared to current cigarette-smoking men. 
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7 Future perspectives
As the years pass, more patients will experience aSAH after participation in the HUNT and 
Tromsø studies. This will increase the power and precision of estimates from these studies, 
which will open the possibility to study subgroups, for instance whether risk factors differ for 
different types of aneurysms, such as aneurysms in the anterior and posterior circulation.
Also, as full-blood samples are available for all participants at baseline, it will be 
possible to perform studies on genes associated with aSAH. Although it is well-known that 
genetic factors play an important part in the genesis of intracranial aneurysms, the genetic 
basis is poorly understood. Identifying susceptible genes may give better understanding of the 
formation and rupture of intracranial aneurysms, and may also lead to development of 
pharmacological therapies.247 Our prospective population studies with verified aSAH cases 
may contribute to this field.
The decision whether to surgically or endovascularly treat unruptured intracranial 
aneurysms or follow them conservatively is a controversy in neurosurgery. The prevalence of 
unruptured intracranial aneurysms is uncertain because of selection bias in earlier studies, and 
it is seen as unethical to study the natural course of high-risk unruptured intracranial 
aneurysms. Therefore, the knowledge about rupture risk, as well as the factors that may 
increase rupture risk, remain uncertain. In HUNT 3, 1000 participants aged 50 to 65 years
underwent MRI including angiography. There is information on incidence of aSAH in the 
same population, and it is therefore possible to estimate rupture risk of unruptured intracranial 
aneurysms. The participants of the MRI study also participated in HUNT 1 and 2, and the 
association of life style factors with the risk of unruptured intracranial aneurysms can be 
assessed.
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